期刊
CANCER CELL
卷 20, 期 4, 页码 423-425出版社
CELL PRESS
DOI: 10.1016/j.ccr.2011.10.006
关键词
-
资金
- NCI NIH HHS [R01 CA046413, P50 CA095103] Funding Source: Medline
The EGFR-directed antibody cetuximab has proven, albeit modest, clinical benefit as monotherapy in head and neck and colorectal cancers. In a recent study, Yonesaka et al. uncovered a new mechanism of cetuximab resistance mediated by increased ERBB2 signaling via amplification of ERBB2 or increased levels of the ERBB3/ERBB4 ligand heregulin.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据